Canada – Pfizer Canada is pleased to announce that IXIFI® (infliximab for injection) will be available in Canada as of April 1. IXIFI® is a biosimilar to Remicade® (infliximab.) IXIFI® was approved by Health Canada in December 2021 for all eligible indications of the reference product, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease (in adults and pediatric patients 9 years and older), fistulising …